Do you want to read an article? Please log in or register.
Integrating Quality of Life and Survival in Systemic Therapy for Advanced Hepatocellular Carcinoma: A Network Meta-Analysis
Further Publications
Related content
Genitourinary Cancer
A Meta-Analysis and Meta-Regression of the Efficacy, Toxicity, and Quality of Life Outcomes Following Prostate-Specific Membrane Antigen Radioligand Therapy Utilising Lutetium-177 and Actinium-225 in Metastatic Prostate Cancer
Eur Urol
Dai YH, Chen PH, Lee DJ, Andrade G, Vallis KA
doi: 10.1016/j.eururo.2024.09.020
RECOMMENDED
Gynecologic Cancer
First-line treatment of locally advanced cervical carcinoma: An updated systematic review and Bayesian network meta-analysis
★ 1
Recommended by
Prof. Dr Beat Thürlimann, Faculty Member
Cancer Treat Rev
Petrelli F, Riboldi V, Bruschieri L, Villa A, Cribiu' FM, Borgonovo K, Ghilardi M, Ghidini A, Seghezzi S, Stefani A, Trevisan F
doi: 10.1016/j.ctrv.2025.102921
Genitourinary Cancer
Health-related quality of life with belzutifan versus everolimus for advanced renal cell carcinoma (LITESPARK-005): patient-reported outcomes from a randomised, open-label, phase 3 trial
Lancet Oncol
Powles T, Choueiri TK, Albiges L, Peltola K, de Velasco G, Burotto M, Suarez C, Ghatalia P, Iacovelli R, Lam ET, Verzoni E, Gümüş M, Stadler WM, Kollmannsberger C, Melichar B, Venugopal B, Gross-Goupil M, Poprach A, De Santis M, Rizzo M, Shinde R, Saretsky TL, He L, Perini RF, Vickery D, Rini B
doi: 10.1016/S1470-2045(25)00032-4
Gastrointestinal Cancer
NOTCH1 Mutation and Survival Analysis of Tislelizumab in Advanced or Metastatic Esophageal Squamous Cell Carcinoma: A Biomarker Analysis From the Randomized, Phase III, RATIONALE-302 Trial
J Clin Oncol
Lu Z, Du W, Jiao X, Wang Y, Shi J, Shi Y, Shu Y, Niu Z, Hara H, Wu J, Hsu CH, Van Cutsem E, Brock MV, Zhang Z, Ding N, Zhang Y, Shen Z, Shen L
doi: 10.1200/JCO-24-01818
Gastrointestinal Cancer
Circulating tumor DNA as prognostic marker in patients with metastatic colorectal cancer undergoing systemic therapy: A systematic review and meta-analysis
Cancer Treat Rev
Holz A, Paul B, Zapf A, Pantel K, Joosse SA
doi: 10.1016/j.ctrv.2025.102999
Central Nervous System Tumors
Benchmarking the Efficacy of Salvage Systemic Therapies for Recurrent Meningioma: A RANO Group Systematic Review and Meta-analysis to Guide Clinical Trial Design
Neuro Oncol
Kotecha R, Akdemir EY, Kutuk T, Ilgin C, Ahluwalia MS, Bi WL, Blakeley J, Dixit KS, Dunn IF, Galanis E, Galldiks N, Huang RY, Johnson DR, Kaley TJ, Kamson DO, Kurz SC, McDermott MW, Odia Y, Preusser M, Raizer J, Reardon DA, Rogers CL, Ruda R, Schiff D, Vogelbaum MA, Weller M, Wen PY, Mehta MP
doi: 10.1093/neuonc/noaf009
Genitourinary Cancer
Comparative efficacy and safety of ablative therapies in the management of primary localised renal cell carcinoma: a systematic review and meta-analysis
Lancet Oncol
Huang RS, Chow R, Benour A, Chen D, Boldt G, Wallis CJD, Swaminath A, Simone CB 2nd, Lock M, Raman S
doi: 10.1016/S1470-2045(24)00731-9
Skin Cancer
Safety of adoptive therapy with tumor-infiltrating lymphocytes and high-dose recombinant interleukin-2 in advanced cutaneous melanoma: a systematic review and meta-analysis
Ann Oncol
Martín-Lluesma S, Dafni U, Vervita K, Karlis D, Dimopoulou G, Tsourti Z, Villacampa G, Galvao V, Lostes J, Muñoz-Couselo E, Rotxés M, Villalobos X, Muñoz S, Haanen JBAG, Svane IM, Piulats JM, Martin-Liberal J, Gros A, Coukos G, Garralda E
doi: 10.1016/j.annonc.2025.04.001
Lung, Respiratory and Thoracic Cancer
Comparative effectiveness and safety of tislelizumab versus other anti-PD-(L)1 agents in first- and subsequent lines in locally advanced or metastatic non-small cell lung cancer: Systematic literature review and network meta-analysis
Lung Cancer
Girard N, Han JY, Soo RA, Wang K, Tang W, Nikolaidis GF, Tasoulas A, Barouma I, Castro JC, Yang Z, Chaudhary T, Zhan L
doi: 10.1016/j.lungcan.2025.108450